PARP inhibition in BRCA2-mutated prostate cancer

Ann Oncol. 2017 Jan 1;28(1):189-191. doi: 10.1093/annonc/mdw445.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • BRCA2 Protein / genetics*
  • Germ-Line Mutation*
  • Humans
  • Male
  • Middle Aged
  • Phthalazines / therapeutic use*
  • Piperazines / therapeutic use*
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Prostatic Neoplasms, Castration-Resistant / genetics*

Substances

  • BRCA2 Protein
  • BRCA2 protein, human
  • Phthalazines
  • Piperazines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • olaparib